Dysentery, Amebic

Determination the prevalence of Entamoeba histolytica infections among patients at Assiut University Hospitals presented with diarrhea/dysentery.
Evaluatation the role of different cultures in diagnosing Entamoeba .
Molecularly differentiation between Entamoeba species to monitor the true prevalence of E.histolytica .

主要研究目的 考察健康受试者在空腹及餐后条件下，单次口服1片由山东鲁抗医药集团赛特有限责任公司生产的奥硝唑片（受试制剂T，规格：0.5g）与相同条件下单次口服1片由OrPha Swiss GmbH持证的奥硝唑片（参比制剂R，商品名：Tiberal®，规格：0.5g）的药动学特征，评价两制剂的生物等效性，为该受试制剂一致性评价提供依据。 次要研究目的 观察健康受试者在空腹及餐后条件下单次口服0.5g的受试制剂奥硝唑片（规格：0.5g）与参比制剂奥硝唑片（商品名：Tiberal®，规格：0.5g）的安全性。

Amoebiasis, an infection by the protozoan parasite Entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. It is estimated that E. histolytica may infect half a billion people annually. Moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. Laboratory diagnosis of E. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. Microscopy is time consuming and requires an experienced observer to identify the organism. Furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. Therefore, a few the commercially available copro-antigen assay have been developed for E. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ICT) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost.
The aim of the study is:
to evaluate the efficacy of commercially available rapid immunochromatographic Copro-antigen assay (RIDA® QUICK Entamoeba) in comparison with conventional microscopic examination for the diagnosis of E. histolytica /dispar infection.
to estimate the prevalence of E. histolytica /dispar infection in outpatients in Sohag.